Entest BioMedical, Inc. Sees Substantial Opportunities in Treatment of Chronic Obstructive Pulmonary Disease

$170 Billion projected to be spent over next 5 years for COPD related medical costs

Entest foresees potentially large revenue stream from its COPD Treatment

• Press Release
• Source: Entest BioMedical, Inc.
• On 10:01 am EST, Thursday November 5, 2009

SAN DIEGO--(BUSINESS WIRE)--David Koos, Chairman and CEO of Entest BioMedical, Inc. (OTCBB: ENTB - News), stated that the Company’s unique treatments for Chronic Obstructive Pulmonary Disease (COPD), currently in development, can lead to substantial revenue opportunities. According to Koos, “Current treatment for COPD is aimed at improving quality of life, not curing the illness. It is Entest’s goal to reverse the damage from COPD. If successful, Entest stands to profit substantially from the money currently spent on maintenance treatments that are not cures.”

Related Quotes

Symbol	Price	Change
ENTB.OB	0.83	0.00

{"s" : "entb.ob","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The Company stated that over the next 5 years over $170 billion will be spent on treating COPD in the United States. Currently COPD is the 4^th leading cause of death in the United States and is projected to become the 3^rd leading cause of death in the US by 2020. It is estimated that COPD medical related costs will be in excess of $800 billion during the next 20 years.

David Koos also stated, “It is clear that both in the near term and further out any company demonstrating efficacy in treating COPD has a great chance to participate in the billions of dollars that are and will be spent treating COPD. We believe our patent pending treatment model represents not only a ‘mitigating treatment’ but could provide a ‘regenerative treatment’ for patients. COPD is a progressive, non-reversible disease. Our researchers believe using a photoceutical device to direct stem cells to targeted damaged lung tissue may actually reverse the impact of COPD.”

The uniqueness of Entest’s model involves “painting” damaged tissue with the photoceutical device, which then guides the stem cells to the desired areas. This focused approach allows for concentration of the stem cell treatment. This advanced treatment approach relies on stem cell therapy which requires FDA approval and photoceutical devices that are currently being used in treating other illnesses.

Entest is seeking grant funding in excess of $3 million to support its research and is applying for government development contracts.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB - News) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN - News). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-therapies for cancer, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Entest BioMedical Inc.
David R. Koos, Chairman & CEO
619-702-1404 Direct
619-330-2328 Fax
info@EntestBio.com
www.EntestBio.com